Roche upgraded by UBS to buy on growth outlook
UBS has upgraded Roche (OTCQX:RHHBY) to buy from neutral, citing the company's growth outlook. "We see sustained outperformance of Vabysmo and Ocrevus as key drivers of near-term growth, with ...
UBS raises AppLovin stock price target to $630, maintains buy
UBS analyst Chris Kuntarich increased the price target for AppLovin Corp (NASDAQ: NASDAQ:APP) to $630 from the previous target of $440, while sustaining a Buy rating on the stock. The revision ...
The CSL share price hit a 52-week low this week. Is it time to buy?
This week, the CSL Ltd (ASX: CSL) share price hit a 52-week low. Should investors view the ASX healthcare share as a buy?
Compass upgraded to Buy at UBS on acquisition benefits, expected market share gains
UBS upgraded Compass (COMP) to Buy on the premise that the real estate brokerage stock isn't reflecting the company's recent ...
Wells Fargo Recruits $1.6 Billion Advisor Team From UBS
Wells Fargo Advisors, the bank’s brokerage unit, recruited a former UBS advisor team that oversaw $1.6 billion in assets ...